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Abstract Suppressors of cytokine signaling (SOCS) proteins
possess common structures, a SOCS box at the C-terminus and a
SH2 domain at their center. These suppressors are inducible in
response to cytokines and act as negative regulators of cytokine
signaling. The ASB proteins also contain the SOCS box and the
ankyrin repeat sequence at the N-terminus, but do not have the
SH2 domain. Although Socs genes are directly induced by
several cytokines, no Asb gene inducers have been identified. In
this study, we screened the specific genes expressed in the course
of differentiation of HL-60 cells, and demonstrated that ASB-2,
one of the ASB proteins, was rapidly induced by all-trans retinoic
acid (ATRA). Typical retinoid receptors (RARs) or retinoid X
receptors (RXRs) binding element (RARE/RXRE) were pre-
sented in the promoter of the Asb-2 gene. We showed that
RARK, one of the RARs, binds to the RARE/RXRE in the Asb-2
promoter. In addition, we demonstrated by luciferase reporter
assay that this element was a functional RARE/RXRE. These
findings indicate that ASB-2 is directly induced by ATRA and
may act as a significant regulator, underlying such physiological
processes as cell differentiation. ß 2001 Federation of Euro-
pean Biochemical Societies. Published by Elsevier Science B.V.
All rights reserved.
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1. Introduction
Suppressors of cytokine signaling (SOCS) proteins comprise
a family of intracellular inhibitors of cytokine signal trans-
duction [1^3]. SOCS proteins are characterized by a central
SH2 domain and a C-terminal motif termed the SOCS box [4].
SOCS proteins inhibit cytokine signaling via direct interac-
tions with JAK kinases or cytokine receptors [3,5]. The SH2
and the N-terminal domains of SOCS proteins are important
for this activity. The SOCS box functions to mediate interac-
tion with the elongin B and C complex, and acts as an adapter
interacting with the proteasomal pathway [6]. Other proteins
containing the SOCS box but di¡ering from SOCS proteins in
the combination domain have also been identi¢ed [4]. The
ASB, WSB and SSB proteins contain ankyrin repeats, WD-
40 repeat and SPRY domain, respectively, in their N-termi-
nals and possess the SOCS box at the C-terminal. Although it
is likely that these proteins may also potentially interact to
speci¢c proteins via their N-terminal domains, the target pro-
teins and physiological e¡ects of these remain unclear. In
addition, while the expression of Socs genes is induced by
several cytokines and growth factors, the primary regulator
for other SOCS box family genes is unknown.
Human myelocytic leukemia HL-60 cells have been exten-
sively studied as an experimental model of the molecular
mechanisms of leukemic and myelocytic cell di¡erentiation.
In response to treatment with all-trans retinoic acid
(ATRA), HL-60 cells di¡erentiate into a granulocytic lineage
in vitro [7]. In addition, 1K,25(OH)2D3 or 12-O-tetradecanoyl
phorbol-13-acetate (TPA) are capable of inducing HL-60 cells
into monocytes [8,9]. In ATRA-stimulated di¡erentiation,
ATRA binds to retinoid receptor (RAR) K, which forms a
heterodimer with retinoid X receptor (RXR) [10]. This com-
plex in turn binds to a speci¢c DNA responsive element
(RARE/RXRE) present in the regulatory region of the target
gene. In general, this element consists of a direct repeat of the
core consensus hexamer, AGGTCA [11,12]. C/EBP O and
p21WAF1/CIP1 have been reported to be the target gene of
ATRA, and to be related to leukemia di¡erentiation [13,14].
Despite numerous ¢ndings regarding ATRA action, ATRA
target genes aside from these and its downstream mechanisms
are poorly understood.
To identify novel di¡erentiation-related genes, we devel-
oped a novel approach that analyzes di¡erentially expressed
genes [15]. Using this method, we identi¢ed several genes dif-
ferentially expressed in ATRA-treated HL-60 cells. We found
that the expression of ASB-2, one of the ASB proteins, was
rapidly induced by ATRA. Here we report the ¢rst evidence
that Asb-2 is a target gene of ATRA that is induced during
di¡erentiation of HL-60 cells through the activation of its
RARE/RXRE.
2. Materials and methods
2.1. Cells and treatment
Human myeloblastic leukemia HL-60 cells and mouse F9 cells were
cultured with a medium containing 10% heat-inactivated fetal calf
serum in a humidi¢ed atmosphere of 5% CO2^95% air. We used
RPMI 1640 medium (Nissui, Tokyo, Japan) for HL-60 cells and Dul-
becco’s modi¢ed Eagle’s medium (Nissui) for F9 cells. For the di¡er-
entiation-inducing experiment, HL-60 cells (1^2U105 cells/ml, 9 ml/10
cm dish) were precultured for 16 h, then di¡erentiation inducers were
added (1 ml of inducer-containing medium/10 cm dish). To induce
granulocytic di¡erentiation, HL-60 cells were treated with 1 WM
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ATRA for the indicated period. To induce monocytic di¡erentiation,
HL-60 cells were treated with 100 nM 1K,25(OH)2D or 10 ng/ml TPA
for the indicated period. The di¡erentiation response was monitored
by morphological change, increase in NBT-reducing activity and ex-
pression of surface markers.
2.2. Improved di¡erential display (DD) analysis
Improved DD was performed as described previously [15]. In brief,
HL-60 cells were treated with 1 WM ATRA for 0, 4, 8 and 12 h. 10 Wg
of total RNAs from di¡erentiation-induced HL-60 cells was reverse-
transcribed. Double-stranded cDNA was then synthesized and di-
gested using Sau3AI. Fragments were ligated to an adapter composed
of long (5P-CGGGTAAGGGGTCGACATGAGTGT-3P) and short
(5P-GATCACACTCATGT-3P) oligonucleotides. The ligated 3P-end
fragments from the cDNA pool were selectively ampli¢ed by PCR
using an FITC-labeled oligo dT extended primer and an adapter ex-
tended primer. PCR products were loaded onto 6% denaturing poly-
acrylamide gel and visualized using a FluorImager (Amersham Phar-
macia, CA, USA).
2.3. Northern blot analysis
10 Wg of total RNAs was electrophoresed on formaldehyde-MOPS
1.5% agarose gel. RNAs separated in the gel were capillary-trans-
ferred to a nylon membrane (Hybond N ; Amersham Pharmacia)
and crosslinked by UV irradiation. The blot was probed with
32P-labeled speci¢c DNA probe for ASB-2, GAPDH or 18S rRNA.
The mRNA signals were detected and analyzed using a BAS1500 Mac
radio imaging system (Fuji Film, Tokyo, Japan).
2.4. Preparation of antibody and Western blot analysis
For antibody production in rabbit, a synthetic peptide, MI-
KEGKNLAEPNKEGC, was conjugated to keyhole limpets hemocya-
nin using 3-maleimidobenzoic acid N-hydroxysuccinimide ester re-
agent. Cell lysates of HL-60 cells treated by 1 WM ATRA for the
indicated periods were prepared by using lysis bu¡er composed of
50 mM Tris^HCl, 150 mM NaCl, 1% NP40, 0.5 mM dithiothreitol
(DTT), 1 Wg/ml pepstatin, 2 Wg/ml leupeptin and 0.5 mM PMSF, pH
8.0. SDS^PAGE was carried out by the method of Laemmli, and the
proteins in the gel were transferred to a polyvinyl di£uoride (PVDF)
membrane. The membrane was probed with the anti-ASB-2 IgG fol-
lowed by peroxidase-conjugated second antibody. Immunoreactive
bands were visualized using the ECL system (Amersham Pharmacia).
2.5. Electrophoretic mobility shift assay (EMSA)
Nuclear extracts were prepared according to the method of Schrei-
ber et al. [16]. For EMSA, binding reactions were carried out in a
reaction bu¡er composed of 12 mM HEPES, 5 mM MgCl2, 60 mM
KCl, 0.5 mM DTT, 2 Wg of poly(dI-dC), pH 7.9 and 10 fmol of
labeled probe, with 10 or 20 Wg of nuclear extract in a volume of
20 Wl. After incubation for 30 min on ice, protein^DNA complexes
were separated electrophoretically at 4‡C. The gel was dried and la-
beled complexes were detected by a radio imaging system. To observe
competition of probe^protein binding or supershift of probe^protein
bands, cold DNA fragment or antibodies against transcriptional fac-
tors were used.
2.6. Transfection and luciferase reporter assay
The plasmids used for transfection were derived from a SV40 pro-
moter-bearing vector (PGV-P2; Toyo Inc. Co., Tokyo, Japan).
RARE/RXRE-like DNA fragment from the Asb-2 promoter was
cloned upstream from the SV40 promoter. All constructs were veri¢ed
by sequencing the relevant portions. Transient transfection with re-
porter DNA to F9 cells was performed in 12-well culture plates by the
calcium phosphate method. After 24 h treatment with ATRA, cell
lysates were prepared, and luciferase activity in the lysates was mea-
sured on a Luminometer (EG and G Berthold, Bed Wildbad, Ger-
many). The transfection experiments were performed in triplicate us-
ing di¡erent preparations of DNA. Luciferase activity of the cells was
normalized by their protein contents.
3. Results
3.1. Newly identi¢ed Asb-2 gene di¡erentially expressed in
ATRA-treated human leukemia HL-60 cells
We identi¢ed several novel genes di¡erentially expressed in
ATRA-treated human leukemia HL-60 cells using our newly
developed method (Table 1). We focused on the Asb-2 gene,
originally identi¢ed by Kile et al. [17], as it showed the most
rapid induction in response to ATRA treatment. The length
of the original cDNA sequence for human ASB-2 (accession
no. AF159164) was 1640 bp, but the mRNA signal detected in
our Northern blot analysis suggested it to be longer (about
3 kb). Therefore, we cloned human ASB-2 cDNA containing
the full length of the coding region, and de¢ned its sequence
(Fig. 1A). The open reading frame was composed of 1758 bp,
which encoded 585 amino acids (Fig. 1B). The deduced struc-
ture contains nine ankyrin repeats and a SOCS box.
3.2. ASB-2 mRNA expression in HL-60 cells treated by
di¡erentiation inducer
Next, we analyzed the change in expression of ASB-2
mRNA in response to treatment with several di¡erentiation
Table 1
Identi¢cation of the di¡erentially expressed transcripts in HL-60 cells after ATRA treatment
Clone Similar sequence Northern blot
1124A Human mRNA for ¢ve-lipoxygenase activating protein mRNA *
1132A Novel transcription factor (termed ATF9, unpublished) Down
1133A Human mRNA for granulin Up
1323A Homo sapiens basement membrane induced gene (ICB-I) mRNA Up
1323B Homo sapiens phK II-1 (hHb1 gene) Down
1431A Homo sapiens CGI-96 protein mRNA Up
1442A Homo sapiens Src-like adapter protein mRNA *
3141A Human mRNA for lymphocyte-speci¢c protein 1 *
3211B Homo sapiens monocyte chemotactic protein-3 mRNA Down
3241A Human laminin receptor mRNA *
3241D Homo sapiens DAP12 mRNA Up
3323A Homo sapiens DKFZp762B195 mRNA Down
4131A Homo sapiens amyloid L (A4) precursor-like protein 2 mRNA Up
4134A Human eosinophil granule major basic protein mRNA Down
4144A Homo sapiens ankyrin repeat-containing protein ASB-2 mRNA Up
4224A Human mRNA for 90 kDa heat-shock protein *
4231A Unknown Up
4232A Human mRNA for CLP Up
4242B Human mRNA for testis enhanced gene transcript protein Up
4312A Human mRNA for properdin Up
*These transcripts of which di¡erential expression (up-regulation) was already reported in HL-60 cells by ATRA.
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inducers. When HL-60 cells were treated with ATRA, ASB-2
mRNA was induced 4 h after treatment and continued to
increase until at least 72 h later (Fig. 2, upper panel). TPA,
a monocytic inducer of HL-60 cells, also induced ASB-2
mRNA as well as ATRA, but the induction potency was
weaker than that of ATRA (Fig. 2, lower panel). However,
ASB-2 mRNA was not induced by 1K,25(OH)2D3, one of the
monocytic inducers of HL-60 (data not shown). We next ex-
amined the tissue speci¢city of ASB-2 expression. In skeletal
muscle, but not in the heart, brain, kidney, liver, lung, pan-
creas and spleen, a signal from ASB-2 mRNA was shown
(data not shown).
3.3. Identi¢cation of ASB-2 protein in HL-60
To con¢rm the expression of the ASB-2 protein, an anti-
body against a synthetic peptide (MIKEGKNLAEPNKEGC)
from the amino acid sequence of ASB-2 was developed. West-
ern blotting of the extract from HL-60 cells with anti-ASB-2
IgG was performed, and an immunoreactive 65 kDa band was
detected, as shown in Fig. 3. The estimated size of the immu-
noreactive band was close to the value (65 kDa) estimated
based on the nucleotide sequence of ASB-2 cDNA. Immuno-
reactivity in the HL-60 cells was time-dependently increased
upon ATRA treatment.
3.4. Direct regulation of ASB-2 gene expression by ATRA
We found that cycloheximide blocks TPA-induced expres-
sion of ASB-2 mRNA, but does not block ATRA-induced
expression (data not shown). We thus examined whether
ATRA directly regulates expression of the Asb-2 gene. By
Fig. 1. Nucleotide sequence of ASB-2 cDNA and its deduced amino acid sequence. A: Nucleotide sequence of ASB-2 cDNA (accession no.
AB056723). Initiation and termination codons are underlined. B: Deduced amino acid sequences of ASB-2. Ankyrin repeat is indicated by a
single underline and the SOCS box is indicated by a double underline.
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searching for a RARE/RXRE consensus sequence (DR5) in
the Asb-2 promoter, we found a RARE/RXRE-like sequence
at 3132/3116 (Fig. 4A). The half site of this element consists
of 5P-AGGACA-3P instead of 5P-AGGTCA-3P, which is the
consensus sequence of RARE/RXRE. Thus, we analyzed
whether the RARE/RXRE-like sequence in the Asb-2 pro-
moter was recognized by nuclear receptors. As shown in
Fig. 4B, nuclear extracts from HL-60 cells form speci¢c
shifted bands bound with a RARE/RXRE-like sequence in
the Asb-2 promoter. The formation of the shifted bands (in-
dicated by arrow heads) was competitively inhibited by addi-
tion of cold probe and cold DR5. Supershift analysis using
anti-RARK (Fig. 4C) showed that the shifted band (band B)
contained RARK. These results showed that RARK binding
to ATRA acts at the RARE/RXRE-like sequence in the Asb-2
promoter.
3.5. Response of RARE-like sequence in the ASB-2 promoter
to ATRA
To determine whether the RARE/RXRE-like sequence in
the Asb-2 promoter is functional, we inserted four copies of
this element upstream of the SV40 promoter linked to the
luciferase gene. The construct was introduced into F9 cells,
and then response to ATRA was analyzed. The RARE/
RXRE-like sequence in the Asb-2 promoter showed signi¢cant
response to ATRA (Fig. 5). A control vector without the
RARE/RXRE-like sequence did not respond to ATRA. These
¢ndings indicate that ASB-2 is directly induced by ATRA.
Fig. 3. Identi¢cation of ASB-2 protein in HL-60 cells by Western
blotting. HL-60 cell lysates were prepared and subjected to SDS^
PAGE (7.5% gel, 6 Wg protein/lane), blotted onto PVDF membrane.
Immunochemical detection was carried out with anti-ASB-2 IgG
and ECL system.
Fig. 2. Expression of ASB-2 mRNA in ATRA-treated HL-60 cells.
HL-60 cells were treated with 1 WM ATRA or 10 ng/ml TPA for
the indicated periods. Total RNAs (10 Wg/lane) were subjected to
Northern blot analysis. GAPDH was used as internal control.
Fig. 4. EMSA of a RARE-like sequence in the ASB-2 promoter.
A: Deduced ASB-2 promoter sequence derived from the human ge-
nomic working-draft sequence is shown. Potential RARE/RXRE is
underlined. The 5P-untranslated region of ASB-2 is capitalized.
B and C: Nuclear extract was prepared from HL-60 cells. RARE/
RXRE-like sequence in the Asb-2 promoter was used as a probe in
the double strand form. 32P-labeled probe was incubated with 10
(C) or 20 (B) Wg of nuclear extract for 30 min on ice. Competition
binding assays (B) were performed by 20-, 40- or 80-fold molar ex-
cess of indicated cold DNA. In supershift analysis (C), nuclear ex-
tracts were preincubated with 2 Wg of control or anti-RARK IgG
overnight on ice.
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4. Discussion
In the present study, we isolated a number of genes di¡er-
entially expressed in ATRA-induced di¡erentiation of HL-60
cells, and showed that the transcript encoding ASB-2 was
rapidly induced after ATRA treatment. We also showed
that Asb-2 was the target gene of ATRA.
ATRA has been shown to induce di¡erentiation of normal
myeloid and myeloid leukemia cells into mature cells through
the activation of the RARK nuclear receptor, which also acts
as a transcription factor [7,18]. In most cases of acute pro-
myelocytic leukemia (APL), the RARK gene is altered by
chromosomal translocations leading to the synthesis of chi-
meric proteins, e.g. PML/RARK or PLZF/RARK [19,20].
These chimeras strongly suppress the activation of RARK,
by which the leukemic phenotype might be triggered [21].
Despite accumulating data regarding chimeric proteins, rela-
tively little is known about the target genes of RARK or how
RARK induces myeloid cell di¡erentiation. Here, we found a
functional RARE/RXRE in the Asb-2 gene promoter and
showed that RARK acts at this element. These ¢ndings indi-
cate that the Asb-2 gene is a novel RARK target gene. Thus,
we believe that ASB-2 proteins participate in RARK-mediated
myeloid cell di¡erentiation. More detailed analysis is needed
to clarify this ¢nding.
Due to prominent induction of ASB-2 mRNA by ATRA,
we expected that ASB-1 and ASB-3 would also be induced by
the same stimulation. However, reverse transcription PCR
analysis revealed that the mRNAs of ASB-1 and ASB-3
were not induced by ATRA treatment (data not shown), in-
dicating that the regulation of ASB proteins by ATRA is
restricted to ASB-2. It remains to be determined what the
di¡erent inducers of ASB-1 and ASB-3 are, or alternatively,
whether a common inducer of ASB proteins exists, as with
cytokines for SOCS proteins. Our study demonstrated that
TPA also induced the mRNA of ASB-2. Terstegen et al. re-
ported that TPA induced SOCS-3 mRNA within 45 min after
treatment [22]. They showed that this expression was triggered
by extracellular signal-regulated kinases 1 and 2. However,
because of delayed induction of ASB-2 mRNA compared
with SOCS-3, we believe that the mechanism of ASB-2
mRNA induction by TPA di¡ers from that of SOCS-3.
It has been demonstrated that the tumor suppressor gene
product of von Hipple^Lindau disease, which also possesses
the SOCS box, forms a complex with both elongin B/C com-
plex and cullin-2, both of which function as ubiquitin ligases
[6,23,24]. As the SOCS box of ASB and SOCS proteins are
capable of interacting with the elongin B/C complex, the ASB
and SOCS proteins have been hypothesized to function as
part of the ubiquitin ligase complex contributing to ubiquitin
transfer to target proteins. TEL^Jak2 fusion oncoprotein is
known to possess constitutive tyrosine kinase activity and
transforming properties in hematopoietic cells [25]. Recently,
three groups independently reported that TEL^Jak-mediated
transformation of hematopoietic cells was inhibited by SOCS-
1 proteins through the induction of proteasome-mediated deg-
radation [26^28]. Moreover, Yoshikawa et al. indicated that
human hepatocellular carcinomas, in which interleukin-6
stimulates malignant progression via JAK/STAT activation,
are caused by the aberrant methylation of Socs-1 CpG, and
constitutive activation of the JAK/STAT pathway is associ-
ated with silencing of Socs-1 [29]. These results suggest that
SOCS-1 proteins play a tumor suppressor role. Based on their
structural similarity to SOCS proteins and the expression pro-
¢le on di¡erentiation of HL-60 cells, it is likely that ASB
proteins also interact with speci¢c proteins via their ankyrin
repeats, and that they could play a signi¢cant role, such as
tumor suppression. Therefore, the next important step in this
line of research is to identify ASB-2-regulated ankyrin repeat
binding factor(s).
In conclusion, we found that ASB-2 mRNA is induced by
ATRA, and that it is directly regulated by RARK and RARE/
RXRE in the promoter region of the Asb-2 gene. Its inducing
pro¢le, function and characteristic structure suggest that
ASB-2 might be an important regulator of di¡erentiation
and/or proliferation of myeloid cells.
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